Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

In the relapsed setting for patients with T-cell lymphoma, there are several doublet-based trials with romidepsin (Istodax), Fanale explains. There are plans to do randomized trials to compare 2 doublets versus romidepsin on its own.

Right now, a lot of the active clinical trials in the frontline setting look at a combination of chemotherapy plus one of the targeted agents, states Fanale. One of the eagerly awaited clinical trials is the ECHELON-2 trial, which focused on the combination of brentuximab vedotin (Adcetris) with CHP compared with CHOP, which is the standard of care. It has now completed enrollment but has not yet met its primary endpoint for progression-free survival.

Michelle A. Fanale

Articles

Dr. Fanale on Clinical Trials for T-Cell Lymphoma